We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novenesis AS (PK) | USOTC:NVZMY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.40 | -0.70% | 57.12 | 56.02 | 57.86 | 57.57 | 56.71 | 56.86 | 12,141 | 22:00:01 |
From Jan 2020 to Jan 2025
Danish bio-technology firm Novozymes A/S (NZYM-B.KO) Thursday reported a 13% jump in third-quarter net profit and raised its full-year outlook for both operating and net profit.
Third-quarter net profit rose to 639 million Danish kroner ($109 million) from 568 million kroner in the year-earlier quarter, on revenue of 3.18 billion kroner, compared to 2.94 billion kroner a year ago.
Quarterly operating profit was 831 million kroner, up from 755 million kroner.
The company said it now expects full year operating profit to grow by 14%-15%, and full year net profit to grow by 13%-14%, partly driven by a favorable development in currency exchange rates and a slightly higher contribution from The BioAg Alliance.
Previously, Novozymes expected full-year net and operating profit to increase by 9%-11% on the year.
-Write to Jens Hansegard at jens.hansegard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Novenesis AS (PK) Chart |
1 Month Novenesis AS (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
